COV has superior specificity and sensitivity and is more progressed albeit for the pre-surgical indication vs general screening with hopefully FDA approval early next year . IIQ still requires large trials in the general population (and the associated $$) and FDA approvals.
Ignoring all that simply put head to head - sensitivity and specificity of 95% in COV and IIQ is 77%/95%
Ann: CLEO to Fast Track Development of Ovarian Cancer Test, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $29.78M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 36.5¢ | $32.04K | 85.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 356 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 3839 | 1 |
View Market Depth
| Last trade - 15.50pm 08/08/2025 (20 minute delay) ? |
| COV (ASX) Chart |